Extension Study of ABP-19000 to Evaluate Safety and Efficacy of Repeat Treatments of ABP-450 in Cervical Dystonia

PHASE2CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

July 27, 2021

Primary Completion Date

July 24, 2023

Study Completion Date

July 24, 2023

Conditions
Cervical Dystonia
Interventions
DRUG

ABP-450

ABP-450 (prabotulinumtoxinA) contains a 900kDA botulinum toxin type-A complex produced by the bacterium Clostridium botulinum.

Trial Locations (20)

30329

Emory University, Atlanta

32792

Neurology One, Winter Park

33024

Infinity Clinical Research LLC, Hollywood

33176

Brainstorm Research, Miami

33613

University of South Florida, Tampa

37232

Vanderbilt University Medical Center, Nashville

38157

Veracity Neuroscience LLC, Memphis

43054

The Orthopedic Foundation, New Albany

44195

The Cleveland Clinic Foundation, Cleveland

48334

Quest Research Institute - Hunt - PPDS, Farmington Hills

48824

Michigan State University, East Lansing

60612

Rush University Medical Center, Chicago

77030

Baylor College of Medicine, Houston

85032

Arizona Neuroscience Research, Phoenix

87106

University of New Mexico, Albuquerque

89106

Cleveland Clinic Lou Ruvo Center for Brain Health, Cleveland

92354

Loma Linda University, Loma Linda

92708

Parkinson's and Movement Disorder Institute, Fountain Valley

93710

Neuro Pain Medical Center, Fresno

06905

New England Institute for Neurology and Headache, Stamford

Sponsors
All Listed Sponsors
lead

AEON Biopharma, Inc.

INDUSTRY